An unheard mobilization of resources to find SARS-CoV-2 vaccines and therapies has been
sparked by the COVID-19 pandemic. Two years ago, COVID-19's launch propelled mRNA …

The year 2023 marks the 25 th anniversary of the discovery of RNA interference (RNAi).
RNAi-based therapeutics enable sequence-specific gene knockdown by eliminating target …

Despite the worldwide success of mRNA-LNP Covid-19 vaccines, the nanoscale structures
of these formulations are still poorly understood. To fill this gap, we used a combination of …

mRNA LNPs can experience a decline in activity over short periods (ranging from weeks to
months). As a result, they require frozen storage and transportation conditions to maintain …

Lipid nanoparticles (LNPs) have been widely investigated for nucleic acid therapeutic
delivery, and demonstrated their potential in enabling new mRNA vaccines. LNPs are …

Despite their successful implementation in the COVID-19 vaccines, lipid nanoparticles
(LNPs) still face a central limitation in the delivery of mRNA payloads: endosomal trapping …

The field of gene therapy has evolved and improved so that today the treatment of
thousands of genetic diseases is now possible. An integral aspect of the drug development …

The development of mRNA delivery systems utilizing lipid-based assemblies holds immense
potential for precise control of gene expression and targeted therapeutic interventions …

Lipid nanoparticles (LNPs) have emerged as a promising delivery system, particularly for
genetic therapies and vaccines. LNP formation requires a specific mixture of nucleic acid in …

In this study, we synthesized a novel compound, agmatine-cholesterol conjugate (AG-Chol),
to enhance the anti-tumor activity of drug-loaded liposomes. We replaced cholesterol with …